Last reviewed · How we verify

Kaposi's Sarcoma Skin Lesions — Treatment Landscape & Competitive Intelligence

Kaposi's Sarcoma Skin Lesions (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Kaposi's Sarcoma Skin Lesions, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Panretin ALITRETINOIN Advanz Retinoid [EPC] Retinoic acid receptor beta 1999-01-01
Retin-A TRETINOIN Bausch Health Retinoid [EPC] Nuclear receptor ROR-beta 1971-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Advanz · 1 drug in Kaposi's Sarcoma Skin Lesions
  2. Bausch Health · 1 drug in Kaposi's Sarcoma Skin Lesions

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Kaposi's Sarcoma Skin Lesions:

Cite this brief

Drug Landscape (2026). Kaposi's Sarcoma Skin Lesions — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/kaposi-s-sarcoma-skin-lesions. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing